Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Central Park Medical College

Status: Completed

Conditions: LDL - Low Density Lipoprotein Receptor Disorder; Rosuvastatin

Treatments: Drug: Rosuvastatin

Study type: Interventional

Funder types: Other

Identifiers

NCT06910098

PHRF/RCT/238

Details and patient eligibility

About

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Enrollment: 195 patients

Sex: All

Ages: 30+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

patients who were already on statins

Exclusion criteria

hereditary diseases including familial hypercholesterolemia and kidney diseases

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

195 participants in 3 patient groups

Group 1

Experimental group

Description:

receiving drug dose of 5mg

Treatment:

Drug: Rosuvastatin

Drug: Rosuvastatin

Drug: Rosuvastatin

Group 2

Active Comparator group

Description:

receiving grug dose of 10 mg

Treatment:

Drug: Rosuvastatin

Drug: Rosuvastatin

Drug: Rosuvastatin

Group 3

Active Comparator group

Description:

receiving dose of 20 mg

Treatment:

Drug: Rosuvastatin

Drug: Rosuvastatin

Drug: Rosuvastatin